We also implemented our Targeted Cancer Drug Development Platform, which is aimed at producing proprietary cancer drugs that are designed to inhibit multiple validated cancer pathway targets. In order to increase our medicinal chemistry capabilities to meet the expected needs of this drug development platform, we entered into a collaborative relationship with a leading chemistry provider in Shanghai, China and are currently contracting approximately 25 to 30 chemists to advance our proprietary compounds. We anticipate that we will select our first lead clinical candidate from our drug development platform in the first half of 2007 and that we will file an IND for this clinical candidate in late 2007 or early 2008. We plan to seek a corporate collaborator for the first successfully selected drug candidate that will provide us with significant involvement in at least the early stages of clinical testing.”

All I can say is you better get a good deal on this